JP7559257B2 - 抗ｃｄ３０ｌ抗体およびその使用 - Google Patents

抗ｃｄ３０ｌ抗体およびその使用 Download PDF

Info

Publication number
JP7559257B2
JP7559257B2 JP2023549602A JP2023549602A JP7559257B2 JP 7559257 B2 JP7559257 B2 JP 7559257B2 JP 2023549602 A JP2023549602 A JP 2023549602A JP 2023549602 A JP2023549602 A JP 2023549602A JP 7559257 B2 JP7559257 B2 JP 7559257B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
set forth
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023549602A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509746A (ja
Inventor
フェクト，ジェシー－ファラ
レンショー，マーク
フランソン，ヨハン
ローラン，オリヴィエ
バーネット，バートン
Original Assignee
プロメテウス バイオサイエンシーズ，インク．
ドクター．フォーク ファーマ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロメテウス バイオサイエンシーズ，インク．, ドクター．フォーク ファーマ ゲーエムベーハー filed Critical プロメテウス バイオサイエンシーズ，インク．
Publication of JP2024509746A publication Critical patent/JP2024509746A/ja
Priority to JP2024160401A priority Critical patent/JP2025004013A/ja
Application granted granted Critical
Publication of JP7559257B2 publication Critical patent/JP7559257B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023549602A 2021-02-17 2022-02-16 抗ｃｄ３０ｌ抗体およびその使用 Active JP7559257B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024160401A JP2025004013A (ja) 2021-02-17 2024-09-17 抗ｃｄ３０ｌ抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150373P 2021-02-17 2021-02-17
US63/150,373 2021-02-17
PCT/US2022/016565 WO2022177963A1 (en) 2021-02-17 2022-02-16 Anti-cd30l antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024160401A Division JP2025004013A (ja) 2021-02-17 2024-09-17 抗ｃｄ３０ｌ抗体およびその使用

Publications (2)

Publication Number Publication Date
JP2024509746A JP2024509746A (ja) 2024-03-05
JP7559257B2 true JP7559257B2 (ja) 2024-10-01

Family

ID=82931610

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023549602A Active JP7559257B2 (ja) 2021-02-17 2022-02-16 抗ｃｄ３０ｌ抗体およびその使用
JP2024160401A Pending JP2025004013A (ja) 2021-02-17 2024-09-17 抗ｃｄ３０ｌ抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024160401A Pending JP2025004013A (ja) 2021-02-17 2024-09-17 抗ｃｄ３０ｌ抗体およびその使用

Country Status (19)

Country Link
US (3) US20240254246A1 (enExample)
EP (1) EP4294840A4 (enExample)
JP (2) JP7559257B2 (enExample)
KR (1) KR20230157356A (enExample)
CN (2) CN117255802A (enExample)
AR (1) AR124895A1 (enExample)
AU (1) AU2022224561A1 (enExample)
BR (1) BR112023016445A2 (enExample)
CA (1) CA3208060A1 (enExample)
CL (1) CL2023002393A1 (enExample)
CO (1) CO2023011962A2 (enExample)
CR (1) CR20230445A (enExample)
EC (1) ECSP23070234A (enExample)
GE (3) GEAP202416351A (enExample)
IL (1) IL305146A (enExample)
MX (1) MX2023009621A (enExample)
PE (1) PE20231680A1 (enExample)
TW (1) TW202302637A (enExample)
WO (1) WO2022177963A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025004013A (ja) * 2021-02-17 2025-01-14 プロメテウス バイオサイエンシーズ，インク． 抗ｃｄ３０ｌ抗体およびその使用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4081241A4 (en) 2019-12-24 2024-05-01 Juvena Therapeutics, Inc. REGENERATIVE POLYPEPTIDES AND THEIR USES
IL309562A (en) 2021-06-21 2024-02-01 Juvena Therapeutics Inc Regenerative polypeptides and their uses
AU2023315888A1 (en) * 2022-07-25 2025-02-06 Dr. Falk Pharma Gmbh Anti-cd30l antibodies, formulations therefor, and uses thereof
WO2024143497A1 (ja) * 2022-12-28 2024-07-04 国立大学法人京都大学 Ｃｄ１５３を標的とする医薬組成物
WO2025059023A1 (en) * 2023-09-12 2025-03-20 Amgen Inc. Anti-cd30l antibodies and uses thereof
WO2025075049A1 (ja) * 2023-10-03 2025-04-10 国立大学法人京都大学 ヒトｃｄ１５３を標的とする抗体ならびにキメラ抗原受容体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013163377A1 (en) 2012-04-27 2013-10-31 Novo Nordisk A/S Human cd30 ligand antigen binding proteins

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
DK0615451T3 (da) * 1992-05-26 2006-04-24 Immunex Corp Hidtil ukendt cytokin der binder til CD30
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005018571A2 (en) 2003-08-20 2005-03-03 University Of Miami Compositions and methods for treating inflammatory lung disease
WO2013059732A1 (en) * 2011-10-21 2013-04-25 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
EP3356415B1 (en) * 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
WO2017127537A1 (en) 2016-01-19 2017-07-27 Thomas Blumenthal Down syndrome biomarkers and uses thereof
KR20250111409A (ko) * 2018-04-30 2025-07-22 세다르스-신나이 메디칼 센터 염증성 질환을 보유하는 환자의 선택 및 치료를 위한 방법 및 시스템
WO2020096046A1 (ja) 2018-11-09 2020-05-14 国立大学法人大阪大学 老化関連ｔ細胞を標的とした糖代謝異常の予防または治療用ワクチン
AU2022224561A1 (en) 2021-02-17 2023-09-28 Dr. Falk Pharma Gmbh Anti-cd30l antibodies and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013163377A1 (en) 2012-04-27 2013-10-31 Novo Nordisk A/S Human cd30 ligand antigen binding proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Herold EM. et al.，Sci Rep，2017年，Vol. 7:12276

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025004013A (ja) * 2021-02-17 2025-01-14 プロメテウス バイオサイエンシーズ，インク． 抗ｃｄ３０ｌ抗体およびその使用

Also Published As

Publication number Publication date
CA3208060A1 (en) 2022-08-25
EP4294840A4 (en) 2025-06-11
US11866505B2 (en) 2024-01-09
AR124895A1 (es) 2023-05-17
WO2022177963A1 (en) 2022-08-25
CN118047872A (zh) 2024-05-17
CN117255802A (zh) 2023-12-19
IL305146A (en) 2023-10-01
GEAP202516710A (en) 2025-05-13
TW202302637A (zh) 2023-01-16
CO2023011962A2 (es) 2023-09-29
CL2023002393A1 (es) 2024-03-22
AU2022224561A9 (en) 2023-10-05
JP2025004013A (ja) 2025-01-14
US20230060624A1 (en) 2023-03-02
US20240254246A1 (en) 2024-08-01
US20240092923A1 (en) 2024-03-21
GEAP202416351A (en) 2024-02-12
AU2022224561A1 (en) 2023-09-28
KR20230157356A (ko) 2023-11-16
ECSP23070234A (es) 2023-10-31
JP2024509746A (ja) 2024-03-05
EP4294840A1 (en) 2023-12-27
MX2023009621A (es) 2023-10-31
BR112023016445A2 (pt) 2023-12-12
PE20231680A1 (es) 2023-10-19
GEP20257791B (en) 2025-09-10
CR20230445A (es) 2023-11-14

Similar Documents

Publication Publication Date Title
JP7559257B2 (ja) 抗ｃｄ３０ｌ抗体およびその使用
JP7442443B2 (ja) 多重特異性抗体
KR20170049554A (ko) Cd123 결합제 및 그의 용도
JP7419238B2 (ja) Ｐｄ１結合剤
JP2024513921A (ja) 抗ｃｄ１２２抗体及びその使用
KR20250057935A (ko) Pdl1 표적화 항체 및 이의 사용 방법
KR20200008614A (ko) 항체-사이토카인 생착된 단백질 및 면역 관련 장애를 위한 사용 방법
WO2021143914A1 (zh) 一种激活型抗ox40抗体、生产方法及应用
TW202328183A (zh) 人類介白素-4受體α抗體
JP2025020172A (ja) Ｃｄ１３７を標的とする抗体およびその使用方法
CN114269435A (zh) Cd47肿瘤选择性结合的抗体工程
US20250002576A1 (en) Claudin 18.2-binding antibodies and fragments thereof
US20250340660A1 (en) Anti-cd30l antibodies, formulations therefor, and uses thereof
WO2025077831A1 (en) Anti-il-4ra/tslp antibodies and uses thereof
RU2786730C2 (ru) Белки на основе антитела с привитым цитокином и способы их применения при иммунных нарушениях
CN121226557A (zh) 抗cMET抗体
CN121226555A (zh) 抗cMET抗体
CN116284406A (zh) 一种pd-1结合蛋白及其应用
CN117295762A (zh) 抗cd122抗体及其用途
HK40068966A (en) Engineering of an antibody for tumor-selective binding of cd47
EA046142B1 (ru) Антитела к trem-1 и их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240220

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240815

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240828

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240918

R150 Certificate of patent or registration of utility model

Ref document number: 7559257

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150